p-Methylphenyl potassium sulfate
(Synonyms: 对甲基硫酸钾; p-Tolyl sulfate potassium) 目录号 : GC31519A sulfate conjugate of p-cresol
Cas No.:91978-69-7
Sample solution is provided at 25 µL, 10mM.
p-Cresol sulfate is a sulfate conjugate of the uremic toxin p-cresol, which is formed by bacterial fermentation of proteins in the large intestine.1,2 p-Cresol sulfate increases migration and proliferation of isolated rat aortic vascular smooth muscle cells (VSMCs) when used at a concentration of 500 ?M.3 It also increases the area of aortic atherosclerotic plaques in nephrectomized ApoE-/- mice fed a high-fat diet when administered at a dose of 100 mg/kg per day via the drinking water. Serum levels of total and free p-cresol sulfate are increased in patients with advanced stage chronic kidney disease and positively associated with vascular calcification.4
1.Smith, E.A., and Macfarlane, G.T.Enumeration of human colonic bacteria producing phenolic and indolic compounds: Effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolismJ. Appl. Bacteriol.81(3)288-302(1996) 2.Meijers, B.K.I., and Evenepoel, P.The gut-kidney acis: Indoxyl sulfate, p-cresyl sulfate and CKD progressionNephrol. Dial. Transplant.26(3)759-761(2011) 3.Han, H., Chen, Y., Zhu, Z., et al.p-Cresyl sulfate promotes the formation of atherosclerotic lesions and induces plaque instability by targeting vascular smooth muscle cellsFront. Med.10(3)320-329(2016) 4.Liabeuf, S., Barreto, D.V., Barreto, F.C., et al.Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney diseaseNephrol. Dial. Transplant.25(4)1183-1191(2010)
Cas No. | 91978-69-7 | SDF | |
别名 | 对甲基硫酸钾; p-Tolyl sulfate potassium | ||
Canonical SMILES | O=S(OC1=CC=C(C)C=C1)([O-])=O.[K+] | ||
分子式 | C7H7KO4S | 分子量 | 226.29 |
溶解度 | DMSO : ≥ 300 mg/mL (1325.73 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.4191 mL | 22.0955 mL | 44.1911 mL |
5 mM | 0.8838 mL | 4.4191 mL | 8.8382 mL |
10 mM | 0.4419 mL | 2.2096 mL | 4.4191 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet